Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases
Susanne Schnittger,
Ulrike Bacher,
Tamara Alpermann,
Andreas Reiter,
Madlen Ulke,
Frank Dicker,
Christiane Eder,
Alexander Kohlmann,
Vera Grossmann,
Andreas Kowarsch,
Wolfgang Kern,
Claudia Haferlach,
Torsten Haferlach
Affiliations
Susanne Schnittger
MLL Munich Leukemia Laboratory, Munich
Ulrike Bacher
MLL Munich Leukemia Laboratory, Munich;Department for Stem Cell Transplantation, University of Hamburg
Tamara Alpermann
MLL Munich Leukemia Laboratory, Munich
Andreas Reiter
Medizinische Klinik III, Universitätsmedizin Mannheim, Germany
We analyzed 636 patients with diverse myeloproliferative neoplasms or myelodysplastic/myeloproliferative neoplasms for mutations of the Casitas B-cell lymphoma gene (CBLmut) in exons 8 and 9 and performed correlations to other genetic alterations. CBLmut were detected in 63 of 636 (9.9%) of these selected patients. CBLmut were more frequent in myelodysplastic/myeloproliferative neoplasms than myeloproliferative neoplasms (51 of 328, 15.5% vs. 12 of 291, 4.1%; P
